Business & Finance
McMurry-Heath Named to PerkinElmer Board of Directors
26 July 2022 - - Dr. Michelle McMurry-Heath has been elected to US-based diagnostics, life science research, food, environmental and industrial testing PerkinElmer, Inc's (NYSE: PKI) board of directors, the company said.

A medical doctor and molecular immunologist by training, Dr. Michelle McMurry-Heath assumed a leadership of the biotechnology Innovation Organization as president and CEO in 2020.

She came to BIO from Johnson and Johnson where she served as Global Head of Evidence Generation for Medical Device Companies and then vice president of Global External Innovation and Global Leader for Regulatory Sciences.

Prior to her time at J and J, Dr. McMurry-Heath was also a key science policy leader in government, conducting a comprehensive analysis of the National Science Foundation's policies, programs and personnel.

President Obama then named her associate science director of the FDA's Center for Devices and Radiological Health.

Dr. McMurry-Heath was the founding director of the Aspen Institute's Health, Biomedical Science, and Society Policy Program and received her early training in science policy from the Robert Wood Johnson Foundation.

Dr. McMurry-Heath also serves on the board of directors at Bioventus. She received her MD/PhD from Duke's Medical Scientist Training Program, becoming the first African American to graduate from the prestigious program.

She spent 12 years working at the research bench before taking policy and leadership roles in government and industry.

PerkinElmer offers reagents, assays, instruments, automation, informatics and strategic services meant to accelerate workflows, deliver actionable insights and support improved decision making.

The company reported revenues of approximately USD 5bn in 2021, serves customers in 190 countries, and is a component of the S and P 500 index.